malondialdehyde has been researched along with macelignan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choo, JH; Han, KL; Hwang, JK; Sohn, JH | 1 |
| Li, J; Liu, J; Long, J; Qian, K; Tan, S | 1 |
2 other study(ies) available for malondialdehyde and macelignan
| Article | Year |
|---|---|
Macelignan protects HepG2 cells against tert-butylhydroperoxide-induced oxidative damage.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Comet Assay; DNA Damage; Dose-Response Relationship, Drug; Humans; L-Lactate Dehydrogenase; Lignans; Lipid Peroxidation; Malondialdehyde; Molecular Structure; Myristica; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species; tert-Butylhydroperoxide; Time Factors | 2007 |
Macelignan protects against renal ischemia-reperfusion injury via inhibition of inflammation and apoptosis of renal epithelial cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Biomarkers; Blood Urea Nitrogen; Caspase 3; Catalase; Creatinine; Epithelial Cells; Glutathione; Inflammation; Interferon-gamma; Interleukin-6; Kidney; Lignans; Male; Malondialdehyde; Rats, Sprague-Dawley; Reperfusion Injury; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2020 |